The deadline to have your abstract considered for Oral Presentation has been extended through March 31!
The Program Committee requests abstracts of your research for presentation at SIVB 2021: In Vitro OnLine.
Abstract fees are:
Regular Abstract Submission* $50
Student Abstract Submission $25
*Post Doc and Research Technician abstracts are submitted at the Regular Abstract Submission rate.
Abstracts are accepted in electronic format. SIVB’s online electronic abstract system includes online payment capabilities plus step-by-step instructions for online submission and confirmations. The Deadlines for FINAL abstract submission and to have your abstract considered for oral presentation have been EXTENDED through March 31, 2021. All abstracts submitted from March 5 – March 31 will be considered for presentation as either an Oral or Poster Presentation and published in a fall issue of In Vitro Cellular and Developmental Biology.
Abstract fees are non-refundable.
Invited Speakers should not submit their abstracts through this system. The Meeting Secretariat will contact all Invited Speakers separately with directions on where to submit their invited abstracts.
Submit your abstract to SIVB 2021: In Vitro OnLine
Other Abstract information
Student Abstract Verification Requirement
All abstracts submitted by students will be required to have their supervisor review and approve the submitted abstract in our online system. Students will need to include the name and email address of their professor/supervisor on the Author page when submitting their work. To complete the submission, the student’s supervisor will be sent a an email with a direct link to log into the Scorecard and approve the content and co-authors of the abstract. Once approved, the student will be allowed to log back in, then complete submitting the abstract. Directions for this process will also be provided when submitting your student abstract online.
Rapid Abstract Acceptance
Rapid acceptance is designed for those who need proof of acceptance to apply for funding to register for the meeting. If you request rapid acceptance, SIVB will provide verification of your abstract’s acceptance within two weeks after the submission deadline (March 31). If you are interested in Rapid Abstract Acceptance, please check that option when you submit your abstract online or note it in your cover letter with your hard copy submission. Please note that rapid acceptance only guarantees that your abstract will be presented at the meeting. Decisions as to the type of presentation (whether it will be an oral, interactive poster or poster presentation) will not be provided until spring when the final program is determined.
The Silent Abstract is a special abstract category for authors unable to attend the meeting. Abstracts submitted for the Silent Abstract category follow the same abstract format, abstract fee, and scientific review/acceptance by the program committee; and, if accepted, will be printed in the abstract book. (Note: Please do not submit an abstract for a poster or oral presentation if you are not attending the meeting.)
Interactive Poster Sessions
These presentations have become an integral part of the SIVB meetings. A select group of posters will be chosen to participate in these oral presentation sessions. Each poster presenter will provide a short (5-minute maximum) oral presentation of their poster, after which, the floor will be open for discussion.
Directions for Formatting Your Abstract
Below are directions for formatting your heading and abstract plus a sample for reference to assist you in preparing your submission in advance.
ABSTRACT HEADING DIRECTIONS
Format the 4 sentences of your abstract heading into a SINGLE PARAGRAPH. Formatting instructions for each sentence of the paragraph and a sample heading, which is formatted correctly, are below for your reference:
- First sentence is the title of the abstract and in title case. Hyphenated words should have the second word in lower case.
- Second sentence is the list of authors:
- Presenting author should be listed first and in all capital letters.
- Other authors are not capitalized.
- If there are 2 or more authors, please place the word “and” before the last author’s name.
- If there is more than one affiliation, author’s affiliations should be noted by superscript numbers at the end of their name. Please use numbers 1,2,3,4). Do NOT use letters (a,b,c) or other punctuation (*) to delineate affiliations. If all authors are from the same affiliation, superscripts are not necessary.
- Third sentence is affiliations:
- Please list complete address of affiliation starting with the affiliation.
- If one affiliation, no superscript is necessary; if 2 or more affiliations are listed, please use numerical superscript to delineate each. Superscript should be listed at the beginning of the address.
- Countries should be capitalized. Do not list country if affiliation is in USA.
- If more than two affiliations are listed, please place a semicolon (;) between affiliations and place the word “and” before the last affiliation.
- Fourth sentence is the presenting author’s email address.
- Please begin the sentence with “Email: “
- Do not put a period after the email addresses.
- If the corresponding author is different than the presenting author, both email addresses can be listed.
ABSTRACT BODY DIRECTIONS
- The body of the abstract will be limited to 1,800 characters
- Cited references should be included in the body of the abstract text, and NOT listed at the end.
- There will be no tables, figures, end references or keywords in the body of the abstract. If submitted with these items, they will be removed from the abstract.
A Human in Vitro Model to Study Epigenetic Dysregulations in Non-Communicable Diseases. MAGNOLIA ARIZA-NIETO1, Joshua B Alley2, Laura Fitzgerald2, Sanjay Samy2, Peggy Stock3, Thomas J. VanderMeer2, and Michael L. Shuler1. 1Department of Biomedical Engineering, Cornell University, Ithaca NY; 2Guthrie Clinic, Sayre, PA; and 3University of Leipzig. Leipzig, GERMANY. Email: email@example.com
Obesity is a chronic disease with complex origins. The outcomes of weight loss interventions are highly variable despite diet and physical activity. Furthermore the link between obesity and cancer is not fully understood and the state of the epigenome appears to be a common complication. Our group is working in the development of a human in vitro model to study epigenetic dysregulatory states in a personalized matter by isolating, expanding and differentiating mesenchymal stem cells (MSCs) from each patient donors. The aim of this research was to identify secretory biomarkers in human plasma that would indicate dysregulatory states of the epigenome (episensors) and that could be used both in clinical studies as well as with the human in vitro model. This research is part of the IRB approved clinical trial GHS # 1207-27. The personalized human in vitro model uses cells from patient donors, those cells carry the individual’s complete genome including polymorphisms and epigenetic signatures. MSCs from 3 different sources (circulating in blood, from bone marrow and from visceral adipose tissue) were isolated, expanded and differentiated into hepatocyte-like cells. The model will serve as a tool to test the influence of dietary and pharmacological compounds in the inhibition or activation of target genes in regulatory signaling pathways. In fasting plasma we identified a series of episensors (adiponectin, irisin, CD14 and mature microRNAs), they are still to be assayed in MSCs. We also developed a qPCR based eleven target regulatory signaling panel (ETRSP) that includes the expression of liver DNMT1 known to preserved the patterns of DNA methylation and its function is controlled via SIRT1/PGC1/FNDC5, insulin/PI3K/PTEN/AKT, MAT1/MAT2, the activation of the TLR/CD14 superfamily and the bioavailability of methyl donors. Preliminary results using the episensors together with the ETRSP profiles suggest changes in signaling pathways can be detected and could be used both in vivo and in vitro, as a tool to understand the personalized etiology of non-communicable diseases.